THE ESSENTIAL
- In a letter received by several women in recent weeks, the ANSM warns of the risks associated with the prolonged use of Colprone, a progestin based on medrogestone.
- This treatment, although effective against various gynecological disorders, “can promote the development of a meningioma”, a benign tumor forming from the membranes surrounding the brain.
- The risk is “multiplied by 4 beyond one year of treatment”. Women taking Colprone are advised to consult their doctor so that he or she can assess the need for tests.
“Important health information.” In a letter received by several women in recent weeks, the National Agency for the Safety of Medicines and Health Products (ANSM) is sounding the alarm about the risks associated with the use of Colprone, a progestin based on medrogestone . According to information from 20 Minutesthe treatment could in fact promote the development of a meningioma.
Benign tumors often non-cancerous
Colprone, which contains a hormone similar to progesterone, is primarily prescribed to treat various gynecological disorders. Among them, menstrual irregularities, premenstrual syndrome, breast pain, painful periods, uterine bleeding (particularly those caused by fibroids), endometriosis or even symptoms linked to menopause.
But the ANSM reminds that this treatment, although effective, “may promote the development of a meningioma”a benign tumor forming from the membranes surrounding the brain. The agency specifies that “Most often these tumors are non-cancerous, however they can cause serious complications requiring major surgery.”
The risk associated with this treatment is directly linked to its duration of use. According to the ANSM, a study shows that “the risk of developing a meningioma is multiplied by 4 for medrogestone beyond one year of treatment”. Consequently, women taking Colprone are advised to consult their doctor to assess the need for brain imaging. If the treatment exceeds twelve months, this examination becomes recommended to possibly detect the presence of a meningioma, and regular monitoring by MRI is recommended for prolonged use over several years.
Consult in case of suggestive symptoms
The ANSM also imposes a specific procedure for any renewal of treatment with medrogestone. An information sheet must be given to the patient, and beyond one year of use, a document co-signed by the doctor and the patient is required once a year. “It is essential to obtain your medicine in pharmacies after one year of treatment”specifies the agency.
Finally, in the presence of symptoms suggestive of a meningioma (recurrent headaches, dizziness, visual, hearing, language or memory problems, etc.), it is essential to consult a doctor quickly. If a meningioma is detected, immediate cessation of treatment is required.
Related News :